Cincinnati Wellness Review
SEE OTHER BRANDS

Reporting on health and wellness news in Ohio

Cincinnati Wellness Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cincinnati Wellness Review.

Press releases published on May 8, 2025

VitalHub Reports First Quarter 2025 Results

VitalHub Reports First Quarter 2025 Results

Annual Recurring Revenue (ARR)⁽¹⁾ up 54% YoY to $73.7 million Total Revenue up 42% YoY to $21.7 million Adjusted EBITDA⁽¹⁾ up 39% YoY to $5.6 million TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX: …

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and …

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results …

PacBio Announces First Quarter 2025 Financial Results

PacBio Announces First Quarter 2025 Financial Results

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:   Q1 2025 Q1 2024 Revenue $37.2 million $38.8 million Instrument revenue $11.0 million …

Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that …

Globus Medical Reports First Quarter 2025 Results

Globus Medical Reports First Quarter 2025 Results

AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease …

CooperCompanies to Participate in the William Blair Growth Stock Conference

CooperCompanies to Participate in the William Blair Growth Stock Conference

SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive …

Progyny, Inc. Announces First Quarter 2025 Results

Progyny, Inc. Announces First Quarter 2025 Results

Reports Record Revenue of $324.0 Million, Reflecting 16.5% Growth Raises Full Year Guidance Due to Strong Start to the Year Early Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE …

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the …

Oculis Reports Q1 2025 Financial Results and Provides Company Update

Oculis Reports Q1 2025 Financial Results and Provides Company Update

The recent R…

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted …

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system ( …

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non- …

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call …

Senseonics Holdings, Inc. Reports First Quarter Financial Results

Senseonics Holdings, Inc. Reports First Quarter Financial Results

Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 …

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives …

Fulcrum Therapeutics to Participate in Upcoming May Conferences

Fulcrum Therapeutics to Participate in Upcoming May Conferences

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

  ● Q1 Revenue of $11.5 million; a 13% increase year-over-year   ● Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels   ● Q1 Thyroid test volume up 16% year-over-year to record levels   ● Q1 Thyroid revenue of $8.0M; up …

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering …

CVRx Reports First Quarter 2025 Financial and Operating Results

CVRx Reports First Quarter 2025 Financial and Operating Results

MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service